Clinical trial
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With…
NCT00248482 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00248482 |
|---|---|
| Title | Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| Official title | Phase II Trial of Imatinib Mesylate Maintenance Therapy in Patients With C-Kit (+) Extensive-Stage Small Cell Lung Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin, Gleevec™, irinotecan |
| Enrollment | 6 |
| Start date | Feb 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Nov 4, 2005 |
| Last update posted | Apr 29, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: